Eisai France

What Eisai France does

Eisai France (legally EISAI SAS) is the wholly-owned French operating subsidiary of Eisai Co., Ltd., a Japanese pharmaceutical research and development company founded in 1941 and listed on the Tokyo Stock Exchange (ticker 4523). Established in 1996 as Eisai's first European subsidiary, the company is headquartered in Puteaux (1 terrasse Bellini, 92800) and operates with 119 employees in France, alongside the European Knowledge Center in Hatfield, UK which houses over 650 employees. The French subsidiary is organized around two therapeutic areas: neurology (epilepsy and Alzheimer's disease) and oncology (breast, kidney, thyroid, and endometrial cancers), and markets a portfolio of branded prescription drugs including Aricept (donepezil) for Alzheimer's, Fycompa (perampanel) and Inovelon (rufinamide) for epilepsy, Halaven (eribuline) for breast cancer, and Kisplyx and Lenvima (lenvatinib) for various oncology indications.

The company generates revenue through sales of these prescription pharmaceutical products in France under regulated pricing administered by the CEPS (Comité Économique des Produits de Santé), with distribution through direct hospital pharmacy relationships for oncology products and retail pharmacy channels for outpatient neurology medications. Its go-to-market combines field-based medical representatives and medical science liaisons engaging healthcare professionals (neurologists, oncologists, pharmacists, and GPs) with regulatory-compliant promotional activities certified by AFNOR (valid until January 2027). Eisai France conducts approximately 14 clinical studies locally, representing around 35% of Eisai's worldwide clinical trials, leveraging CNIL-authorized health data infrastructure including the LRX warehouse and SNDS/PMSI databases for real-world evidence generation.

Strategically, the French subsidiary operates under the global Eisai group's 'human health care' (hhc) philosophy, which mandates that employees dedicate 1% of work time to patient engagement, and supports partnerships with patient associations, the Fondation Vaincre Alzheimer, IHU HealthAge Toulouse, and global initiatives such as the WHO filariasis elimination program (since 2013, providing 2.51 billion tablets of diethylcarbamazine) and the Antibiotic Resistance Action Fund. The parent group invests 23% of annual revenue in R&D, above industry average, and operates 14 R&D sites and 9 production sites worldwide, with Eisai France serving as the first and a clinically significant node in the European network of 14 subsidiaries covering 21 countries.

Name

Eisai France

Legal name

EISAI SAS

Website

https://eisai.fr

Company type

Private

Founded year

1941

Operating status

Operating

Headcount range

11–50 employees

Short description

Eisai France (EISAI SAS) is the French subsidiary of Japan's Eisai Co., Ltd., operating in Puteaux with 119 employees. It markets branded neurology (epilepsy, Alzheimer's) and oncology (breast, kidney, thyroid, endometrial) prescription drugs to French healthcare professionals and patients through hospital and retail pharmacy channels.

Ownership category

akta.pro rank

Headquarters

HQ city

Puteaux

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: Eisai generates revenue through the sale of prescription pharmaceutical products in neurology and oncology therapeutic areas. Products include Aricept (donepezil) for Alzheimer's, Fycompa (perampanel) and Inovelon (rufinamide) for epilepsy, Halaven (eribuline) for breast cancer, Kisplyx and Lenvima (lenvatinib) for kidney, thyroid, and endometrial cancers.
2. Licensing and Partnership Royalties: Revenue generated through partnerships with other pharmaceutical companies and licensing agreements for drug compounds and therapeutic technologies, including co-promotion and co-marketing arrangements.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Eisai France (EISAI SAS) is the French operating subsidiary of Japanese pharmaceutical group Eisai Co., Ltd. It develops, markets, and distributes branded prescription pharmaceutical products in two therapeutic areas: neurology (epilepsy and Alzheimer's disease) and oncology (breast, kidney, thyroid, and endometrial cancers). Its portfolio includes Aricept (donepezil), Fycompa (perampanel), Inovelon (rufinamide), Halaven (eribulin), Kisplyx (lenvatinib), and Lenvima (lenvatinib).

Product overview

Eisai France operates as a Japanese pharmaceutical research and development company focused on two key therapeutic areas: neurology and oncology. The company offers a portfolio of branded medications including antiepileptic drugs (Fycompa, Inovelon), Alzheimer's treatment (Aricept), and oncology medications (Halaven, Kisplyx, Lenvima). These products are distributed in France through standard pharmaceutical distribution channels and are promoted to healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

• Aricept (Donepezil) Cholinesterase inhibitor for Alzheimer's disease treatment, available as standard tablets (5mg, 10mg) and orodispersible tablets (5mg, 10mg). Prescribed by neurologists and general practitioners for Alzheimer's patients.
• Fycompa (Perampanel) Antiepileptic medication available as film-coated tablets (2mg, 4mg, 6mg, 8mg, 10mg, 12mg) and oral suspension (0.5mg/mL) for the treatment of epilepsy. Prescribed by neurologists for epilepsy patients.
• Inovelon (Rufinamide) Antiepileptic medication available as tablets (100mg, 200mg, 400mg) and oral suspension (40mg/mL) for epilepsy treatment. Prescribed by neurologists, particularly for Lennox-Gastaut syndrome.
• Halaven (Eribulin) Injectable solution (0.44mg/mL) for the treatment of breast cancer and liposarcoma. Administered in hospital oncology settings.
• Kisplyx (Lenvatinib) Tyrosine kinase inhibitor in capsule form (4mg, 10mg) for the treatment of kidney cancer. Prescribed by oncologists in hospital settings.
• Lenvima (Lenvatinib) Tyrosine kinase inhibitor in capsule form (4mg, 10mg) for the treatment of thyroid cancer and endometrial cancer. Prescribed by oncologists in hospital settings.

Quantifiable outcome

• 23% of annual revenue invested in R&D (above pharmaceutical industry average)
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered major, minor and core.

• IHU HealthAge de ToulousemajorStrategic or Co-development Partner · 1 January 2024Sponsorship agreement with the Hospital-University Institute dedicated to healthy aging, launched in 2024. Supported by CHU de Toulouse, Inserm, and Université Toulouse III. Develops research programs ICOPE and INSPIRE focused on prevention, translational research, and geroscience innovation under France 2030 plan.
• Fond d'action contre l'antibiorésistanceminorStrategic or Co-development Partner · 1 January 2020Eisai participates in the Antibiotic Resistance Action Fund launched in July 2020, committing to make 2 to 4 new antibiotics available to patients as part of global efforts to combat antimicrobial resistance.
• Université de Chicago, Broad Institute, Université du ColoradomajorStrategic or Co-development Partner · 1 January 2018Partnership agreement signed in 2018 for tuberculosis research to develop new treatments. Represents Eisai's commitment to addressing antimicrobial resistance and infectious diseases through international scientific collaboration.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 2013Partnership for filariasis elimination since 2013. Eisai has provided 2.51 billion tablets of diethylcarbamazine free of charge to patients in 32 countries, demonstrating commitment to global health access for neglected tropical diseases.
• Fondation Vaincre AlzheimermajorStrategic or Co-development PartnerPartnership supporting the creation of a clinical trial directory for Alzheimer's and related diseases, managed by Fondation Vaincre Alzheimer and Fédération des Centres Mémoires. Objective is to help patients locate clinical trials in France and strengthen France's role in clinical research.
• LaJaPF (Laboratoires Japonais Présents en France)minorStrategic or Co-development PartnerNon-profit association representing Japanese pharmaceutical laboratories in France, including Eisai, Astellas, Kyowa Kirin, Chugai, Daiichi Sankyo, Otsuka, Santen, and Takeda. Eisai holds seats on the Board of Directors and Bureau of Leem (French pharmaceutical industry association).
• TulipeminorStrategic or Co-development PartnerEisai is a member of Tulipe, an emergency and international solidarity association for healthcare companies. Provides donations to respond urgently to population needs during acute health crises, natural disasters, and conflicts.
• Iqvia Opérations FrancecoreTechnology or IntegrationSubcontractor for health data warehouse analysis (LRX database, CNIL-authorized September 2018). Conducts real-world patient care analysis for Eisai products including Lenvima, in compliance with MR004 methodology.
• Heva SAScoreTechnology or IntegrationQualified research bureau acting as subcontractor for SNDS (National Health Data System) analysis studies. Conducts analysis on antipsychotic medications and psychiatric rehospitalization for Eisai under CNIL authorization.
• CNX TherapeuticsminorOthersEisai transferred Loxapac and Parkinane LP products to CNX Therapeutics Limited (UK) with CNX Therapeutics France SAS as the new marketing authorization holder, effective October 1, 2024. HAC Pharma SAS serves as the French operator.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Roche: Swiss pharmaceutical incumbent with major oncology and neurology presence in France. Roche competes broadly across Eisai's therapeutic areas with oncology assets like Tecentriq and Avastin, but as a much larger diversified incumbent rather than specialty focus.
• AstraZeneca: UK/Swedish pharmaceutical company with major oncology franchise (Tagrisso, Imfinzi, Lynparza) and French presence. AstraZeneca competes in Eisai's oncology areas through hospital pharmacy channels and shares similar regulatory navigation requirements in France.
• Pfizer: US pharmaceutical incumbent with significant oncology (Ibrance, Xtandi) presence in France. Pfizer competes in Eisai's oncology therapeutic area through hospital channels and shares the same regulatory and reimbursement environment in the French market.
• Novartis: Swiss pharmaceutical giant with strong oncology (Kisqali, Lutathera) and neurology presence in France. Novartis competes in Eisai's therapeutic areas but operates as a diversified global incumbent across multiple therapeutic categories beyond Eisai's focus.
• Bristol-Myers Squibb: US pharmaceutical incumbent with strong oncology presence (Opdivo, Yervoy) and French operations. BMS competes in Eisai's oncology therapeutic area through hospital pharmacy channels, particularly in immuno-oncology where Eisai's Lenvima is also positioned.
• Sanofi: French pharmaceutical incumbent headquartered in Paris with broad neurology (epilepsy, multiple sclerosis) and oncology portfolio. Sanofi competes with Eisai France in the same HCP channels but operates a much broader diversified model across multiple therapeutic areas and consumer health.

Direct peers

• Lundbeck: Danish specialty pharmaceutical company with a neurology-only focus (depression, schizophrenia, epilepsy, Alzheimer's). Lundbeck operates in France with a similar specialty pharma commercial model targeting the same HCP segments as Eisai France, making it a close therapeutic-area peer.
• UCB: Belgian specialty pharmaceutical company with strong neurology focus (epilepsy, Parkinson's) and significant French presence. UCB's Vimpat (lacosamide) competes directly with Eisai's Fycompa and Inovelon in the French epilepsy market, and both companies share a specialty pharma model focused on differentiated branded products.
• Biogen: US biotechnology company with strong neurology focus (multiple sclerosis, Alzheimer's, spinal muscular atrophy). Biogen's French subsidiary competes in the same neurology HCP segments as Eisai France, particularly in Alzheimer's disease where both companies have legacy franchises (Biogen's Aduhelm vs. Eisai's Aricept).
• Ipsen: French specialty pharmaceutical company headquartered near Paris with oncology and neurology focus. Ipsen's French heritage and therapeutic focus on oncology (cabozantinib, lanreotide) parallels Eisai France's local presence and oncology strategy, making it a direct local-market peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eisai-france

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eisai France